AzurRx BioPharma Inc. Business Overview

Michael Lane

As an investor and member of numerous investment platforms and communities, I see how valuable investment research can be to better understand current market situation and make more accurate investing decisions.

$AZRX

AzurRx BioPharma Inc. (Nasdaq: AZRX) is a biopharmaceutical company specialized in developing recombinant protein therapies for the treatment of gastrointestinal disorders and microbiome-related conditions. The laboratory serves customers mostly in the U.S. and France, and aims to become a leader in developing non-systemic, recombinant protein therapies.

The health care company, founded in 2014, aims to develop valuable therapies with significant market opportunities, which also generates value for shareholders. In 2021, the laboratory announced an in-licensing agreement with First Wave Bio that introduced a new asset and patented formulations of micronized niclosamide. In addition, the laboratory is launching two clinical programs for the treatment of oncology patients with colitis and diarrhea, and Covid-19 patients with gastrointestinal infections.

During the first quarter of 2021, AzurRX BioPharma raised approximately $18M from the sale of stocks in public offerings and private placement transactions, in addition to receiving $4.6M from the exercise of warrants. Over the past year, the S&P 500 was up 46.13% while AZRX rose 31.82%.

Fast growth

The latest announcements and provision of launches made AZRX rise 41.24% only in January, with a progressive growth till May. The positive results and predictions for 2021 make AzurRX BioPharma shares an attractive option for investors. The company communicates with transparency to its shareholders, which gives more confidence to invest.

More from Top10WallStreet

SumZero Review

Simon Lewis
Financial Analyst

EDITORS' CHOICE

SSI Full in-depth Review

Simon Lewis
Financial Analyst

CoBF Review

Simon Lewis
Financial Analyst

Our Team of Experts

Michael Lane

Head of Research

Simon Lewis

Financial Analyst

Carrie Sanders

Site Editor

AzurRx BioPharma Inc. Business Overview

Michael Lane

$AZRX

During the first quarter of 2021, AzurRX BioPharma raised approximately $18M from the sale of stocks in public offerings and private placement transactions, in addition to receiving $4.6M from the exercise of warrants. Over the past year, the S&P 500 was up 46.13% while AZRX rose 31.82%.

Fast growth

More from Top10WallStreet

SumZero Review

Simon Lewis
Financial Analyst

EDITORS' CHOICE

SSI Full in-depth Review

Simon Lewis
Financial Analyst

CoBF Review

Simon Lewis
Financial Analyst

Our Team of Experts

Our Team of Experts

Michael Lane

Simon Lewis

Carrie Sanders

About

Contact

About

Contact